

Oncology Today with Dr Neil Love: Management of Metastatic Pancreatic Cancer with Dr Michael Pishvaian

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Final analysis of the Phase III POLO trial evaluating active maintenance olaparib versus placebo for patients with metastatic pancreatic cancer and germline BRCA mutations reported statistically significant improvement in which of the following endpoints?**
 - a. Progression-free survival**
 - b. Overall survival
 - c. Both a and b
 - d. Neither a nor b
- 2. In pancreatic cancer, KRAS G12C inhibitors such as sotorasib and adragrasib have approximately what response rate in tumors bearing the KRAS G12C mutation?**
 - a. 10%-20%
 - b. 40%-50%**
 - c. 75%-85%
- 3. The ongoing PANOVA-3 study is evaluating which treatment strategy for locally advanced pancreatic cancer?**
 - a. CAR T-cell therapy
 - b. Claudin 18.2-directed antibody-drug conjugate
 - c. Tumor treating fields**
 - d. Intra-arterial gemcitabine
- 4. Claudin 18.2 positivity by immunohistochemistry staining is detected in what proportion of pancreatic cancer?**
 - a. 5%-10%
 - b. 20%-25%**
 - c. 40%-50%
- 5. The Phase III NAPOLI-3 trial was designed to answer which clinical question for pancreatic cancer?**
 - a. If administering a PARP inhibitor in the adjuvant setting was efficacious in BRCA mutation-positive patients
 - b. If the addition of immunotherapy to a PARP inhibitor as maintenance improved outcomes
 - c. If a 3-drug regimen was more efficacious than a 2-drug regimen as first-line therapy**